VisualMED Will Provide Clinical Workflow Engine for Phase II Clinical Trials
Drug Developers to Benefit From VisualMED Patient Management Process
(firmenpresse) - RENO, NV -- (Marketwire) -- 12/08/11 -- VisualMED Clinical Solutions Corp. (The "Company") (PINKSHEETS: VMCS) (FRANKFURT: VA6) announces it will be providing structured medical content to a provider of software integration services serving major drug developers. The latter seek new forms of standardization designed to both reduce cost and save precious time to market. The use of standardized clinical workflow engine and analysis should have a positive impact in moving forward phase II clinical trials.
The deal is worth $2 M over 2 years for the company and involves mostly formatting and delivery of existing applications and rich medical content. It provides the Company with unprecedented opportunities to sell limited clinical information, a more flexible business model with shorter sale cycle.
"Drug companies are slowly coming around to using solutions that keep pace with the complexities involved in collating information, as we understand more about illnesses and the variable effects of treatment," says Chairman Gerard Dab. "VisualMED has been offering drug companies advanced tools such as one of the industry's best inference engines, medical content and clinical workflow management systems."
The Company intends to offer reduced fixed-term 3rd party licensing at extremely competitive rates for these types of offerings and will determine the appropriate value of this particular solution as it becomes clear how much time and money the pharmaceutical industry can save, in an environment where every day counts against future revenues due to patent limitation.
VisualMED markets smart Clinical Information Systems (CIS) with EHR and Computerized Physician Order Entry that are at the core of the new regulatory environment ushered in by the American Recovery and Reinvestment Act of 2009 and the Health Reform Act of 2010. We offer medical facilities and physicians a broad array of clinical applications with rich embedded clinical data, both scalable and interoperable, and whose high level of usability has been tested by over one thousand clinicians over many years in tertiary care and ambulatory environments. Our solutions help medical facilities increase provider efficiency, bring down operating costs, demonstrate meaningful use for ARRA grants and subsidies, and reduce mortality and morbidity. The Company's Suites of Medical Solutions operate on state of the art proprietary software platforms with advanced analytical capabilities provided by Visual Healthcare Corp. (PINKSHEETS: VSHC).
Detailed information on our company and its products is available on our web site at
FORWARD-LOOKING STATEMENTS
Except for historical information provided herein, this press release may contain information and statements of a forward-looking nature concerning the future performance of the Company. These statements are based on suppositions and uncertainties as well as on management's best possible evaluation of future events. Such factors may include, without excluding other considerations, fluctuations in quarterly results, evolution in customer demand for the Company's products and services, the impact of price pressures exerted by competitors, and general market trends or economic changes. As a result, readers are advised that actual results may differ from expected results.
For further information, please contact:
Gerard Dab
514-582-5220
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 08.12.2011 - 13:22 Uhr
Sprache: Deutsch
News-ID 95066
Anzahl Zeichen: 0
contact information:
Town:
RENO, NV
Kategorie:
Hospitals, Facilities and Providers
Diese Pressemitteilung wurde bisher 310 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"VisualMED Will Provide Clinical Workflow Engine for Phase II Clinical Trials"
steht unter der journalistisch-redaktionellen Verantwortung von
VisualMED Clinical Solutions Corp. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
